Volume : V, Issue : VI, June - 2015

Can Mucocutaneous Ulceration be a Part of Monitoring Guidelines for Methotrexate Toxicity ?

Dr. Sanjiv Choudhary, Dr. Prashant Mahajan

Abstract :

  There are monitoring guidelines to prevent methotrexate toxicity. Pancytopenia and mucocutaneous ulcerations are the important early laboratory and clinical findings of methotrexate toxicity respectively. Mucocutaneous ulceration especially mucositis is an early predictor of methotrexate toxicity well before laboratory evidence. We are reporting three cases of psoriasis vulgaris with methotrexate toxicity. In 1st case, patient developed mucocutaneous erosions after single test dose of methotrexate without myelosupression suggestive of idiosyncratic reaction. In 2nd case, patient took methotrexate for longer duration without any monitoring and developed mucocutaneous ulcerations and myelosupression suggestive of cumulative toxicity. In our 3rd case, patient developed myelosupression and mucocutaneous ulceration due to daily dosing. Mucocutaneous ulceration is the consistant clinical sign of methotrexate toxicity observed in all cases and it can be seen even without myelosupression as in our 1st case. In our opinion, mucocutaneous ulcerations should be included as one of the clinical sign under methotrexate monitoring guidelines

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

Dr. Sanjiv Choudhary, Dr. Prashant Mahajan Can Mucocutaneous Ulceration be a Part of Monitoring Guidelines for Methotrexate Toxicity ? Indian Journal of Applied Research, Vol.5, Issue : 6 June 2015

Number of Downloads : 757

References :